Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Right, then add in a stock split or two for good measure.
Did a recount of the shares to include the Directors and their shares. Here is the result
DIRECTORS
Athanasios Skarpelos 1456458
Christopher Missling 3016638
Bernd Metzner 187500
Elliot Favus 195000
Steffen Thomas 116667
Peter Donhauser
Sandra Boenisch 142158
Directors(Total) 5114421
OS Shares 41376061
TOTAL 13709733 33.13%
A Monday PR for a Wed presentation is realistically possible. Especially if its in another country.
Considering the chances of a Monday PR, most likely we won't even get close to mid $2's.
Monday PR being the conference happening on Wed
If Eisai were smart they WOULD offer a partnership for a % of sales, knowing that the writings are on the wall for their cash cow. Better having a smaller % of Billions than nothing all of a sudden.
So there's the conference in Japan next week where it looks like Missling will present as a company and be on a panel too.
Then there's eom where there's 4 presentations as The sticky says.
Then there's the shareholders meeting early April
Then there's April 20th at terrapinn where Missling presents again. Topic being:
Roundtable 4: Partnerships- successful collaboration between a rare disease foundation and a pharmaceutical company to advance preclinical and clinical research in Rett Syndrome
Christopher Missling, President and Chief Executive Officer, Anavex Life Sciences
- See more at: http://www.terrapinn.com/conference/world-orphan-drug-congress-usa/Conference-Day-Two.stm#sthash.I2ANkfGd.dpuf
That is a pretty stacked schedule. Can't possibly be bad news, right?
Soon to be obsolete SOC?
Ah yes, that looks correct. Sorry everyone for the misunderstanding earlier.
Right next to Anavex presenting as a company stands this:
""Market Outlook:
The Rise of Cross-Asia Partnerships"
Tuesday
3:45PM
https://www.bio.org/sites/default/files/Program%20Schedule%20as%20of%203-7_0.pdf
Yup I'm one too. Although it's not as much as those on the fb group, it is larger than some of the resent tutes that filed last quarter. ????
No selling, just buying and holding as I'm able to.
For a buyout? I think It would take more than that for Missling to release his baby
No worries,
Just trying to make sense and see if this is a company worth investing in. NTRP is on Nasdaq correct? Someone needs to move this board from otc to where it belongs.
I added it to the bottom of my previous post
but here it is
https://fintel.io/so/us/ntrp
just divided everything by 4 to get the new share count since I believe I saw it was a 1:4.
Ahhh. it was a 1:32
http://seekingalpha.com/news/3234931-neurotrope-reverse-split-shares-1-32-today
My count is wrong then.
File Date Investor Current Shares
2017-02-14 Iroquois Capital Management, LLC 717,926
2017-02-13 Neurosciences Research Ventures, Inc. 10,687,500
2017-01-30 Hudson Bay Capital Management LP 5,771,540
2017-01-17 Empery Asset Management, LP 2,542,974
2016-07-14 McGregor Clyde 2,094,450
So the RS was 4:1?
File Date Investor
2017-02-14 Iroquois Capital Management, LLC 179481.5
2017-02-13 Neurosciences Research Ventures, Inc. 2671875
2017-01-30 Hudson Bay Capital Management LP 1442885
2017-01-17 Empery Asset Management, LP 635743.5
2016-07-14 McGregor Clyde 523612.5
After RS, these 5 tutes hold about 5.45 M
https://fintel.io/so/us/ntrp
Are you not concerned that 5 tutes control around 22M shares.
I'm trying to find the outstanding shares but seem to be able to only find January and at that time it was around 6M.
Thats a good point HANUMAN.
That's all nice and dandy, but what benefit is a late stage Alz drug if another drug stabilizes the disease as long as they take it the rest of their lives?
Not trying to put this co down, just a real world scenario.
Everyone does realize if Avxl shows that it halts the disease with a daily pill, there's no need for Bryostatin IV injections right?
If that's so, then why aren't they at conferences or talking at 21 century cures act panel discussions. That is a pretty big deal if trial does help late stage Alz patients. Or is it that pIIA wasn't takin seriously and needed more patients to repeat the results?
Hi NTRP shareholders,
I'd have to agree with blu_1. I've been following AVXL for the last 2 years and they have given nothing but positive results. Although I am rooting for any Alz clinical trial to succeed, most likely you will end up bag holders.
Looking at the IIa trial of NTRP and I have questions such as
1. why are they trying to rush a experimental drug through as if time is
of the essence.
2. Why only 9 participants 6 on Bryo 3 on placebo
3. How is it that placebo could cause these results out of 3 patients,
yet no complaints about any besides a headache for Bryo?
Dizziness 0 1
Headache 1 1
Rash Papular 0 1
Then on the p2,
1. Why only run the trials for 12 weeks, while everyone knows that OVER
TIME, they deteriorate?
2. Principle investigator is a Kenneth Gorelick. Isn't that the same name as Kenny G the saxaphone player? No disrespect, just a lol office space moment.
3. How can kenneth be the priciple investigator and hold shares of the company he is investigating the drug for?
http://www.marketwatch.com/investing/Stock/NTRP/insiders?pid=147413954
It is the number one reason why P3 trials fail, besides the drug being a placebo. Im open to a civilized discussion as I would gladly invest in NTRP if I have faith in the Management.
Correct, but what tom is saying is that it fit perfectly as far as timing and hitting those lower target zones. What comes as selling to some, is a buying opportunity for others.
Lets give the world a April 1st headline that's NO joke.
123Tom thanks for the insight. Added @ 5.52 this dip. Right on point
You misunderstood what I was getting at. It was after the failure, they can start taking a-273 to notice real benefits.
Finally decided to read a foolish article again. These writers either didn't do their DD, or are writing to spook investors. I think the second one. They are trying to make like the company will go at the 3 trials with what "little" money they have. Slyly trying to make the reader assume that the 20M won't cover the trials.
A grant omission here, another grant omission there, and they try to steer the "unsophisticated" investors away from AVXL. Except, now we have big fish ready to swoop in and buy cheap shares.
Ignorance or just plain jealousy of Anavex.
Where's those same postings from when other companies trials misdiagnose patients? Yea that's correct, it doesn't help when BP has nothing better than placebo. Truly showing what effects false hopes does. How about taking Axon 1100 patients after trial failure and giving them something that works, should be approved, and isn't a cocktail of side effects.
If tomorrow happens to be a down day, a few of us members will continue adding to our share count ignoring........
"UNINTELLIGENT BLASPHEMY"
Seriously? That wasn't prd yet . The only thing found was that the same place will be conducting a p2/3 hopefully to kick off this 2017. You think the Aussies don't see the possibilities and are willing to help fund the trial AGAIN?
Why is that LL, because investors are so used to the overbloated costs of a trial that it can't be done in a better more efficient way that the FDA themselves support? Or maybe the amount of patients it takes to find efficacy the old way that they don't understand the new way. FDA says 300 is enough , 300 it is. When you need to break the entire group in smaller groups is when that 1100 patients are positive.
Ahh. Gotcha. Yes, but trying to add up those shares in the filings is beyond my understanding. I could add it to the spreadsheet if anyone wants to make sense of the directors and their amount of shares each.
You saying that they are part of the 20%?
Curious because I added up everyone on fintel and even though it does add up to 20.8 % they aren't listed in the list. And I grabbed the count yesterday.
https://docs.google.com/spreadsheets/d/1MgdA3pUc_7X9JYsH9V0Hs5Pu2JyYQwiUe7cFcsq4qg8
I shared a spreadsheet for the tutes as of feb 28 a couple of posts ago. It is 20.?!!
IMO, I like to think of it as a slight of hand magician trick. Pump up these stocks, make them look attractive. Give them the airtime knowing they will most likely fail.
While this little unknown stock, that is only at $5 is the real pot of gold. No one will believe them that they have the most promising drug if the pps is only $5. If they did, they should be up there like the rest of them.
Then when institutions have majority of the float, and only then will our stock see its true value. Right now it's just like that quote we all hear
"If it sounds too good to be true......."
Except if one goes through the last 1-2 years of this board, they will have done enough dd to know what to do.
Just about what I calculated based on outstanding stock being 41,070,000
https://docs.google.com/spreadsheets/d/1MgdA3pUc_7X9JYsH9V0Hs5Pu2JyYQwiUe7cFcsq4qg8/edit?usp=sharing
Lest not forget about our Directors who have all not sold a share yet isn't added to that list. Then the true longs on the board.
If its any help, heres a link to a lot of companies in that area.
http://www.bio-m.org/fileadmin/user_upload/Publikationen/Geschaeftsbericht_2016_Web_klein.pdf
or perhaps a website explaining the area would be better
https://www.izb-online.de/en/martinsried.html
Does seem like Martinsried is a bio pharma hub
It's encouraging for Anavex shareholders to see that while A-273 seems to work without aricept, Axon is trying to make a possible triple cocktail of Donepezil, glycopyrrolate, and intepirdine. So the same, if not worse side effects will still be had for the patients, while we still have virtually no side effects.
Plus while we try to show efficacy in a p2, they want to monitor gait and balance.
http://www.prnewswire.com/news-releases/axovant-sciences-announces-expansion-of-dementia-pipeline-and-reports-financial-results-for-the-first-fiscal-quarter-ended-june-30-2016-300313586.html
For once, I can't wait till I'm 40 to see how my stock picks worked out.
The better response would be , look, we were in the 2's and you didn't buy. We moved to the 3's and you didn't buy. Now that I've given a noble presentation and other tutes want in you think I'll still give you guys a discount? It's not fair to the shareholders that do believe in this company.
I'm not sure how updated the one I got , but if you copy the first here link and do a google search of the link, you can view the cached version of the site thanks to google by clicking on the little arrow that's pointing down. It's what I did
No it wasn't posted. Thanks for the update. Yes, I remember the conference and how everyone thought nothing came from it.
PR Link HERE
So safe to say Anavex now has a U.S. and EU presence?
Im not so sure as what you are trying to say. If its the justpaste link, I copied and pasted it there.
Would that connect the dots with Anavex GmbH
They did do business with ABX-CRO in p1 and could easily use them again for a different trial.
So many questions